Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661104 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTHCAR3HTTSLC9A1 | |
| SCHEMBL27039743 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTHCAR3HTTSLC9A1 | |
| SCHEMBL15740451 | 0.84 | MAPT (0.40) | ALDH1A1MAPTHCAR3HTTGAA | |
| SCHEMBL15740561 | 0.83 | MAPT (0.46) | ALDH1A1MAPTHCAR3HTTPIN1 | |
| SCHEMBL21680695 | 0.79 | SCN9A (0.35) | — | |
| SCHEMBL21680693 | 0.79 | SCN9A (0.35) | — | |
| SCHEMBL30669758 | 0.79 | SCN9A (0.35) | — | |
| SCHEMBL15740730 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTHCAR3HTTAHR | |
| SCHEMBL17374001 | 0.77 | SYK (0.38) | — | |
| SCHEMBL15740820 | 0.77 | ALDH1A1 (0.36) | ALDH1A1MAPTAHRGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151602-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151728-A1 | LIGAND DIRECTED DEGRADER OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | ALDH1A1 3457/4885MAPT 1801/4885HCAR3 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.